EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, GNPX:

04 Sep 2025
LAST:

0.1557

CHANGE:
 0.01		OPEN:
0.1645		HIGH:
0.1645		ASK:
0.0000		VOLUME:
2.19M
CHG(%):
5.12		PREV:
0.1641		LOW:
0.1520		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
04 Sep 250.16450.16450.15200.15572.19M
03 Sep 250.16000.16810.15850.16412.01M
02 Sep 250.16390.16390.14150.15821.77M
29 Aug 250.17990.17990.14890.16402.74M
28 Aug 250.17300.18200.16950.17474M
27 Aug 250.16910.17800.16500.17273.6M
26 Aug 250.16000.17030.16000.16953.31M
25 Aug 250.18200.18480.16480.16507.38M
22 Aug 250.17060.18870.15660.168397.54M
21 Aug 250.16010.16010.14000.14383.19M

COMPANY PROFILE

Name:
About:Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patient populations with unmet medical needs. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The company's lead product candidate, Reqorsa gene therapy (quaratusugene ozeplasmid), for the treatment of non-small and small cell lung cancer. It is also developing diabetes gene therapy, a novel infusion process that uses an adeno-associated virus vector to deliver Pdx1 and MafA genes directly to the pancreatic duct; GPX-002 for Type 1 diabetes transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has license agreement from the University of Pittsburgh of the Commonwealth System of Higher Education (University of Pittsburgh) multiple technologies relating to the development of a gene therapy product for both Type 1 and Type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Sector:Healthcare
Industry:Biotechnology
Address:3300 Bee Cave Road, Austin, TX, United States, 78746
Website:https://www.genprex.com
CUSIP:372446104
CIK:0001595248
ISIN:US3724461047
FIGI:BBG00F7T0157
LEI:549300KS9771JZ234890

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:0.20
Price to Book:4.59
Shares:33.47M
Market Cap:5.21M

TECHNICAL INDICATORS

MA5:0.16
MA10:0.16
MA20:0.18
MA50:0.23
MA100:0.25
MA200:0.45
STO14:11.22
RSI14:28.54
WPR14:-82.60
MTM14:-0.06
ROC14:-0.27
ATR:0.02
Week High:0.18
Week Low:0.14
Month High:0.26
Month Low:0.14
Year High:3.97
Year Low:0.14

RECENT SPLITS

Date Ratio
02 Feb 20241-40